ADM Tronics Unlimited, Inc. (DMT) – Globe Newswire
-
Disposition of Common Shares of Small Pharma Inc.
-
Small Pharma Reports Fiscal First Quarter 2024 Highlights
-
Small Pharma Announces SPL028 R&D Strategy Update
-
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
-
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
-
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
-
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
-
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
-
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
-
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
-
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
-
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
-
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
-
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
-
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
-
First Patient Dosed in Small Pharma’s Drug Interaction Study
-
Small Pharma To Support University College London Research Project on Neuroplasticity
-
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
-
Small Pharma to Participate in November Investor and Healthcare Conferences
-
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
-
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
-
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
-
Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder
-
Small Pharma Enters Into Automatic Share Purchase Plan
-
Small Pharma to Participate in Upcoming September Investor Conferences
-
Small Pharma Announces TSXV Approval of Normal Course Issuer Bid
-
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
-
Canadian Patent Grant Strengthens Small Pharma’s International Position
-
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
-
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer
-
Small Pharma Reports Fiscal First Quarter 2023 Highlights
-
Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
-
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022
-
Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022
-
Small Pharma Shares Business Update Ahead of Annual Financial Results
-
Small Pharma to Participate in the PSYCH Symposium: London 2022
-
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
-
Small Pharma To Present At The KCSA Psychedelics Virtual Investor Conference On April 28, 2022
-
KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th
-
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
-
Small Pharma to Participate in the 34th Annual Roth Conference
-
World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
-
Small Pharma Reports Fiscal Third Quarter 2021 Highlights
-
Small Pharma to Attend Upcoming Healthcare Conferences in January 2022
-
Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021
-
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
-
Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
-
Small Pharma to Attend Upcoming Healthcare Conferences in November 2021
-
Small Pharma Reports Second Quarter Highlights
-
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders
Back to DMT Stock Lookup
